Yujun Long

139# Renmin Middle RD
Changsha, 410011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Corrigendum to "A comprehensive metabolomic and lipidomic study of olanzapine in the treatment of first-episode schizophrenia" [Asian J. Psychiatry, vol. 105 (2025) 104387].

Corrigendum to "A comprehensive metabolomic and lipidomic study of olanzapine in the treatment of first-episode schizophrenia" [Asian J. Psychiatry, vol. 105 (2025) 104387].

Journal: Asian journal of psychiatry

Published: April 02, 2025

A comprehensive metabolomic and lipidomic study of olanzapine in the treatment of first-episode schizophrenia.

A comprehensive metabolomic and lipidomic study of olanzapine in the treatment of first-episode schizophrenia.

Journal: Asian journal of psychiatry

Published: December 11, 2024

Metformin-improved cognitive impairment in patients with schizophrenia is correlated with activation of tricarboxylic acid cycle and restored functional connectivity of hippocampus.

Metformin-improved cognitive impairment in patients with schizophrenia is correlated with activation of tricarboxylic acid cycle and restored functional connectivity of hippocampus.

Journal: BMC medicine

Published: November 04, 2024

Subgroups of cognitive impairments in schizophrenia characterized by executive function and their morphological features: a latent profile analysis study.

Subgroups of cognitive impairments in schizophrenia characterized by executive function and their morphological features: a latent profile analysis study.

Journal: BMC medicine

Published: May 31, 2024

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial.

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial.

Journal: Lipids in health and disease

Published: March 05, 2024

Exploring the latent cognitive structure in schizophrenia: implications for antipsychotic treatment responses.

Exploring the latent cognitive structure in schizophrenia: implications for antipsychotic treatment responses.

Journal: European archives of psychiatry and clinical neuroscience

Published: November 08, 2023

The Effect of Accelerated Continuous Theta Burst Stimulation on Weight Loss in Overweight Individuals With Schizophrenia: A Double-Blind, Randomized, Sham-Controlled Clinical Trial.

The Effect of Accelerated Continuous Theta Burst Stimulation on Weight Loss in Overweight Individuals With Schizophrenia: A Double-Blind, Randomized, Sham-Controlled Clinical Trial.

Journal: Schizophrenia bulletin

Published: November 03, 2023

The effect of continuous theta burst stimulation on antipsychotic-induced weight gain in first-episode drug-naive individuals with schizophrenia: a double-blind, randomized, sham-controlled feasibility trial.

The effect of continuous theta burst stimulation on antipsychotic-induced weight gain in first-episode drug-naive individuals with schizophrenia: a double-blind, randomized, sham-controlled feasibility trial.

Journal: Translational psychiatry

Published: May 15, 2023

Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia.

Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia.

Journal: Translational psychiatry

Published: May 09, 2023

Minocycline and antipsychotics inhibit inflammatory responses in BV-2 microglia activated by LPS via regulating the MAPKs/ JAK-STAT signaling pathway.

Minocycline and antipsychotics inhibit inflammatory responses in BV-2 microglia activated by LPS via regulating the MAPKs/ JAK-STAT signaling pathway.

Journal: BMC psychiatry

Published: April 19, 2023

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.

Journal: BMC medicine

Published: March 25, 2023

Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.

Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.

Journal: Psychiatry research

Published: November 23, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026